Utility of ICG in Benign Bone Tumors

Summary

Patients with a biopsy-proven benign bone tumor for which standard of care is intralesional operative management will receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) the day prior to surgery during their standard pre-operative clinic visit. On the day of surgery, fluorescence images will be obtained using a non-invasive fluorescence camera.

Timeline

Start

2021-11-11

Primary completion

2022-04-20

Completion

2022-04-20

Drugs

Indications